The IMpower150 study, for example, demonstrated improved PFS of EGFRm NSCLC patients who had disease progression on or did not tolerate an EGFR TKI when they were treated with a combination of chemotherapy, ICI therapy, and VEGF-inhibition as described above (56, 76). Here, EGFR is linked to non-small cell lung carcinoma.